News

Ad-hoc notification in accordance with Section 15 WpHG [Securities Trading Act]: Analytik Jena AG Approves a Subscription Rights Capital Increase of up to 1.95 Million New Shares

04.09.2013 | Ad-hoc-Announcement

Jena (Germany), September 4, 2013 — Today the Executive Board of Analytik Jena AG (“Analytik Jena” Prime Standard: AJA, ISIN: DE0005213508) with the approval of the Supervisory Board has passed a resolution to issue up to 1,950,232 New Shares through a capital increase against cash contributions with subscription rights for shareholders. The subscription ratio will amount to 3:1, meaning that three shares of Analytik Jena equate a subscription right to one New Share. The subscription price was set at EUR 12.50 per New Share. The New Shares will already be entitled to profit participation for financial year 2012/2013. The subscription offer will begin on September 6, 2013, 0:00 AM and end on September 19, 2013, 24:00 PM. IKB Deutsche Industriebank AG will manage the capital increase.

The subscription offer is addressed exclusively to the previous shareholders of Analytik Jena. Exchange trading of subscription rights is not provided. Aside from the subscription offer, the transaction will not involve any additional offers of New Shares, particularly no private placement.

Already prior to the beginning of the subscription offer, Ruesch Holding AG, Unterägeri, Switzerland, has committed to acquiring all New Shares which have not been exercised by the holders of subscription rights during the offer. Analytik Jena therefore assumes that the capital increase will be executed in its entirety. Endress+Hauser AG, Analytik Jena’s largest shareholder, has informed Analytik Jena that Ruesch Holding AG will transfer the New Shares it acquires to a group company of Endress+Hauser AG, after the Bundeskartellamt (German Federal Cartel Office) has issued antitrust authorization for this transfer. If antitrust authorization is denied, Ruesch Holding AG will resell the acquired New Shares at the best possible price to third parties.

Analytik Jena intends to use the expected net proceeds of approximately EUR 23.4 million for various purposes. These purposes include strengthening the equity base, improving liquidity, and ensuring compliance with financial covenants from bond and loan agreements. Furthermore Analytik Jena intends to use portions of the proceeds for potential corporate acquisitions, for expanding the research and development area through cooperative research agreements, for building up and expanding its own international sales structures, and for restructuring subsidiaries.

Upon completion of the capital increase, the registered share capital will increase from approximately EUR 5.71 million currently to approximately EUR 7.66 million. The capital increase is expected to be recorded into the commercial register on September 23, 2013. The New Shares are to be approved for exchange trading on the same day. The listing and delivery of the New Shares are scheduled for September 24, 2013. The execution of the capital increase is contingent on approval of the security prospectus by the German Federal Financial Supervisory Authority (BaFin), which is expected on September 5, 2013.


Contact

Hanna Engelhardt
Media Relations Life Science
+49 (0) 36 41  77-73 55press@analytik-jena.com

The newsletter of Analytik Jena frequently keeps you posted about:

Sign up here